Abstract
Background: Symptom burden is the primary driver for patients with indolent systemic mastocytosis (ISM) to seek medical care, whether or not they are diagnosed. Purpose: This descriptive study aimed to describe the advanced practitioner (AP) and ISM patient perspective relative to the symptom burden of ISM, multidisciplinary diagnosis and management of ISM, barriers to symptom management, strategies for collaborative management of ISM, and communicative health literacy in patients with ISM. Methods: An ISM patient survey and AP survey were developed by an AP-led steering committee incorporating validated tools to measure symptom burden, symptom burden impact, barriers, and strategies for improving symptom burden. Surveys were embedded in Qualtrics and were deployed by Conexiant to a convenience sample of AP members of the Advanced Practitioner Society for Hematology/Oncology (APSHO), AP members of the American Initiative in Mast Cell Diseases, and patients affiliated with The Mast Cell Disease Society between December 22, 2024, and February 3, 2025. Findings: 50 APs and 53 ISM patients completed 100% of the questions on the corresponding surveys. The symptom burden described using the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) to identify the symptoms that are most common, most challenging, and have the greatest impact on quality of life aligns with published data for patients in this survey. Only 24% (n = 13) of ISM patients indicated their disease was well controlled, while 76% of APs indicated greater than 50% of their ISM patients had well-controlled disease (n = 38). Most APs (68%) in the survey indicated they saw one to five ISM patients per year but were comfortable with managing ISM-related symptoms (54%, n = 27). Practice patterns for triage, multidisciplinary management, and shared decision-making are described. Conclusions: This is the first ISM symptom burden–focused survey to provide a direct comparison of patient responses to those of APs in hematology/oncology and allergy and immunology. Indolent systemic mastocytosis symptom burden measurement and symptom burden reduction remain challenging, with several barriers and gaps identified in this study. The APSHO Toolkit for Systemic Mastocytosis, developed in parallel to this study, provides an AP-focused resource for overcoming some of the barriers and gaps identified in this study.
References
Bylund, C. L., Eggly, S., LeBlanc, T. W., Kurtin, S., Gandee, M., Medhekar, R., Fu, A., Khurana, M., Delaney, K., Divita, A., McNamara, M., & Baile, W. F. (2023). Survey of patients and physicians on shared decision-making in treatment selection in relapsed/refractory multiple myeloma. Translational Behavioral Medicine, 13(4), 255–267. https://doi.org/10.1093/tbm/ibac099
Gotlib, J., Castells, M., Elberink, H. O., Siebenhaar, F., Hartmann, K., Broesby-Olsen, S., George, T. I., Panse, J., Alvarez-Twose, I., Radia, D. H., Tashi, T., Bulai Livideanu, C., Sabato, V., Heaney, M., Van Daele, P., Cerquozzi, S., Dybedal, I., Reiter, A., Pongdee, T.,…Maurer, M. (2023). Avapritinib versus placebo in indolent systemic mastocytosis. NEJM Evidence, 2(6), EVIDoa2200339. https://doi.org/10.1056/EVIDoa2200339
Gotlib, J., Gerds, A. T., Abdelmessieh, P., Ali, H., Castells, M., Dunbar, A., Fein Revell, R., George, T. I., Green, S., Gundabolu, K., Hexner, E., Jain, T., Jamieson, C., Kaesberg, P. R., Kuykendall, A. T., Madanat, Y., Manchanda, N., Masarova, L., May, J.,…Hochstetler, C. (2024). NCCN Guidelines® insights: Systemic mastocytosis, Version 3.2024. Journal of the National Comprehensive Cancer Network, 22(Suppl 2). https://doi.org/10.6004/jnccn.2024.0030
Jennings, S. V., Slee, V. M., Zack, R. M., Verstovsek, S., George, T. I., Shi, H., Lee, P., & Castells, M. C. (2018). Patient perceptions in mast cell disorders. Immunology and Allergy Clinics of North America, 38(3), 505–525. https://doi.org/10.1016/j.iac.2018.04.006
Kurtin, S. (2016). Theoretical considerations in the development of a conceptual framework for a mobile health intervention to enhance self-management in older adult cancer survivors [Doctoral dissertation, University of Arizona College of Nursing].
Kurtin, S., Akin, C., George, T. I., & Pearson, E. (2025). Integrating a rare disease into practice: Development of a toolkit for systemic mastocytosis. Journal of the Advanced Practitioner in Oncology. https://doi.org/10.6004/jadpro.2025.16.7.17
Kurtin, S., Lilleby, K., & Spong, J. (2013). Caregivers of multiple myeloma survivors. Clinical Journal of Oncology Nursing, 17(Suppl), 25–32. https://doi.org/10.1188/13.CJON.S2.25-32
LeBlanc, T. W., Baile, W. F., Eggly, S., Bylund, C. L., Kurtin, S., Khurana, M., Najdi, R., Blaedel, J., Wolf, J. L., & Fonseca, R. (2019). Review of the patient-centered communication landscape in multiple myeloma and other hematologic malignancies. Patient Education and Counseling, 102(9), 1602–1612. https://doi.org/10.1016/j.pec.2019.04.028
Osborne, R. H., Batterham, R. W., Elsworth, G. R., Hawkins, M., & Buchbinder, R. (2013). The grounded psychometric development and initial validation of the Health Literacy Questionnaire (HLQ). BMC Public Health, 13, 658. https://doi.org/10.1186/1471-2458-13-658
Padilla, B., Shields, A. L., Taylor, F., Li, X., McDonald, J., Green, T., Boral, A. L., Lin, H. M., Akin, C., Siebenhaar, F., & Mar, B. (2021). Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study. Orphanet Journal of Rare Diseases, 16(1), 434. https://doi.org/10.1186/s13023-021-02037-3
Pardanani, A. (2023). Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. American Journal of Hematology, 98(7), 1097–1116. https://doi.org/10.1002/ajh.26962
Shields, A. L., Taylor, F., Lamoureux, R. E., Padilla, B., Severson, K., Green, T., Boral, A. L., Akin, C., Siebenhaar, F., & Mar, B. (2023). Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF©) and determination of a threshold score for moderate symptoms. Orphanet Journal of Rare Diseases, 18(1), 69. https://doi.org/10.1186/s13023-023-02661-1
Siebenhaar, F., Sander, B., Ho, L. H. T., Ellrich, A., Maurer, M., & Weller, K. (2018). Development and validation of the mastocytosis activity score. Allergy, 73(7), 1489–1496. https://doi.org/10.1111/all.13425
Taylor, F., Akin, C., Lamoureux, R. E., Padilla, B., Green, T., Boral, A. L., Mazar, I., Mar, B., Shields, A. L., & Siebenhaar, F. (2021). Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: The AdvSM-SAF and ISM-SAF(©). Orphanet Journal of Rare Diseases, 16(1), 414. https://doi.org/10.1186/s13023-021-02035-5
Valent, P., Akin, C., Hartmann, K., Alvarez-Twose, I., Brockow, K., Hermine, O., Niedoszytko, M., Schwaab, J., Lyons, J. J., Carter, M. C., Elberink, H. O., Butterfield, J. H., George, T. I., Greiner, G., Ustun, C., Bonadonna, P., Sotlar, K., Nilsson, G., Jawhar, M.,…Metcalfe, D. D. (2021). Updated diagnostic criteria and classification of mast cell disorders: A consensus proposal. Hemasphere, 5(11), e646. https://doi.org/10.1097/hs9.0000000000000646
Valent, P., Akin, C., Sperr, W. R., Horny, H. P., Arock, M., Metcalfe, D. D., & Galli, S. J. (2023). New insights into the pathogenesis of mastocytosis: Emerging concepts in diagnosis and therapy. Annual Review of Pathology: Mechanisms of Disease, 18, 361–386. https://doi.org/10.1146/annurev-pathmechdis-031521-042618
van Anrooij, B., Kluin-Nelemans, J. C., Safy, M., Flokstra-de Blok, B. M., & Oude Elberink, J. N. (2016). Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis. Allergy, 71(11), 1585–1593. https://doi.org/10.1111/all.12920
Yuen, E. Y. N., & Wilson, C. J. (2021). The relationship between cancer caregiver burden and psychological outcomes: The moderating role of social connectedness. Current Oncology, 29(1), 14–26. https://doi.org/10.3390/curroncol29010002
Zeiger, R. S., Tse, K. Y., Li, Q., Saparudin, M., Al-Salman, S. S., Puttock, E. J., Miller, K., Powell, D., Lampson, B., Sullivan, E., & Chen, W. (2025). Patient-reported burden of indolent systemic mastocytosis in a managed care organization. Journal of Allergy and Clinical Immunology: In Practice, 13(1), 202–212.e7. https://doi.org/10.1016/j.jaip.2024.10.021
